Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:DJ
|
| gptkbp:acquired |
gptkb:Illumina,_Inc.
|
| gptkbp:allows |
data analysis complexity
short read lengths error rates in homopolymer regions |
| gptkbp:based_on |
sequencing by synthesis
massively parallel sequencing technology |
| gptkbp:contributed_to |
personalized medicine
|
| gptkbp:developed_by |
gptkb:Solexa,_Inc.
|
| gptkbp:enables |
high-throughput sequencing
|
| gptkbp:has_impact_on |
gptkb:Research_Institute
evolutionary biology pharmacogenomics genomic medicine environmental genomics |
| gptkbp:has_programs |
cancer research
genetic research clinical diagnostics microbial genomics agricultural genomics |
| https://www.w3.org/2000/01/rdf-schema#label |
Solexa
|
| gptkbp:improves |
Illumina technology
|
| gptkbp:introduced |
gptkb:2000
|
| gptkbp:is_associated_with |
data interpretation
research collaborations bioinformatics analysis data storage challenges high-throughput data generation |
| gptkbp:is_compatible_with |
bioinformatics tools
|
| gptkbp:is_influenced_by |
computational biology
advancements in chemistry advancements in optics |
| gptkbp:is_part_of |
clinical trials
international collaborations biomedical research genomic technologies genomic research projects large-scale sequencing initiatives |
| gptkbp:is_recognized_by |
gptkb:Research_Institute
genomics industry |
| gptkbp:is_subject_to |
gptkb:municipality
ethical considerations market competition patent laws |
| gptkbp:is_supported_by |
government funding
private investment |
| gptkbp:is_used_by |
biotechnology companies
research institutions |
| gptkbp:is_used_for |
genome sequencing
|
| gptkbp:provides |
massively parallel sequencing
|
| gptkbp:related_to |
Next-generation sequencing
|
| gptkbp:replaced_by |
Illumina sequencing
|
| gptkbp:utilizes |
fluorescently labeled nucleotides
|
| gptkbp:bfsParent |
gptkb:Illumina
|
| gptkbp:bfsLayer |
4
|